Researchers reviewed the accuracy and characteristics of questionnaire-based PsA screening tools.
Data show that filgotinib is effective for the treatment of active psoriatic arthritis.
Data show an increased prevalence of psoriasis in patients with gout compared with patients without gout.
Patients with rheumatoid arthritis or psoriatic arthritis have a low influenza vaccination rate, despite the recommendation from the CDC to be vaccinated annually.
Christopher T. Ritchlin, MD, MPH, discusses updated bimekizumab data from the BE-ACTIVE trial.
Statin therapy was associated lower CRP levels in psoriatic arthritis treated with statins, possibly indicating decreased systemic inflammation.
No Significant Risk for Atrial Fibrillation, CV Events in PsA Receiving Ustekinumab vs TNF InhibitorsOctober 22, 2018
The primary and secondary outcomes included incident AF or a composite CV event that included myocardial infarction, stroke, and coronary revascularization.
Among a new line of biological and targeted synthetic DMARD, ustekinumab and secukinumab have shown favorable safety and efficacy profiles for psoriasis and arthritis, respectively in patients with psoriatic arthritis.
Patients with psoriatic arthritis had greater entheseal insertion damage scores compared with patients with ankylosing spondylitis.
Investigators assessed radiographic progression in patients with psoriatic arthritis following transition from conventional synthetic disease-modifying rheumatic drugs to anti-tumor necrosis factor-α therapy.
Investigators sought to determine the validity of using a simplified scoring tool that assesses 28 joint counts compared with the original 66/68 joint counts in patients with psoriatic arthritis.
Investigators explore the impact of pregnancy on PsA disease activity, as well as the effect of biologic therapy on PsA disease activity during and following pregnancy.
Risk for type 2 diabetes, ischemic heart disease, and peripheral vascular disease was elevated among patients with psoriatic arthritis compared with the general population.
Results from the RAPID-PsA study showed that patients with PsA who are treated with certolizumab pegol sustained improvements over the course of 4 years when it is taken as a monotherapy or concomitant with DMARDs.
Researchers quantified the incidence of orthopedic procedures in patients with psoriatic arthritis.
Data show that psoriatic arthritis acts as a strong enhancer of age-related catabolic bone damage.
Rheumatologist-assessed inflammatory back pain (IBP) or the criteria for IBP developed for ankylosing spondylitis might not perform well when determining axial involvement in psoriatic arthritis.
Disease activity was altogether low and stable from preconception to 1 year postpartum among pregnant women with psoriatic arthritis.
The safety profile of ixekizumab in the treatment of psoriatic arthritis is similar to the safety profile observed with ixekizumab for the treatment of plaque psoriasis.
Sustained minimal disease activity should be maintained for a prolonged period in order to prevent progression of carotid atherosclerosis and arterial stiffness in patients with PsA.
A final reliable ultrasound score and definition of enthesitis in SpA and PsA were produced by the OMERACT group.
Treatment with secukinumab over 24 weeks led to a decrease of synovial inflammation and no progression of catabolic and anabolic bone changes in patients with PsA.
The overall safety profile of ixekizumab in psoriatic arthritis remained consistent with that reported in the initial 24-week, double-blind study period.
ABT-122 demonstrated acceptable tolerability and maintenance of efficacy at 36 weeks in patients with RA or PsA receiving background methotrexate.
Minimal disease activity provided a stable and valid assessment of clinical status over the course of 24 months in patients with psoriatic arthritis.
Sonographic enthesitis scoring instruments have been developed for spondyloarthritis, but only a few have been validated in psoriatic arthritis.
Researchers sought to estimate the occurrence of psoriatic arthritis in patients with psoriasis.
Widespread nonarthritic pain is linked to worse patient-reported and composite psoriatic arthritis activity measures.
Researchers analyzed the characteristics of patients with psoriatic arthritis with and without axial involvement.
Health-related quality of life was diminished in psoriatic arthritis at time of diagnosis compared with the general population.
Rheumatology Advisor Articles
- 5-Step Guide to Activity Tracker Use for Patients With Rheumatic Diseases
- Gout Associated With Worse Outcomes in Obstructive Coronary Artery Disease
- Filgotinib Effective for Treatment of Active Psoriatic Arthritis
- Standard Set of Outcomes Developed for Value-Based Health Care in Inflammatory Arthritis
- Clinically Meaningful Improvement in Rheumatoid Arthritis Assessed With RAPID-3
- Circadian Rhythm in Rheumatoid Arthritis: Using Chronotherapy to Improve Outcomes
- Transcutaneous Electrical Nerve Stimulation Reduces Pain, Fatigue in Fibromyalgia
- Aspirin, Anticoagulants Similarly Prevent VTE After TKA
- Study: Cold Weather Joint Pain and Other Weather-Related Pain
- Increased Opioid Prescribing Linked to Chronic Usage in Patients With RA
- Treatment Retention Rates Lower in Patients Switching From Originator to Biosimilar Etanercept
- Climate Change Expected to Lead to Rise in Lyme Disease
- Red Cell Distribution Width Linked to Cardiovascular Disease Risk Factors in Spondyloarthritis
- Higher Biologic Drug Survival in JIA With Younger Age at Treatment Initiation
- Enough Is Enough? When Health Metrics Shift From Useful to Too Much